Is pharmacokinetic guidance a must in busulfan regimens?

Lancet Haematol. 2018 Nov;5(11):e498-e499. doi: 10.1016/S2352-3026(18)30171-6.

Author

Yoshinobu Kanda¹

Affiliation

¹ Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Tochigi 329-0498, Japan. Electronic address: ycanda-tky@umin.ac.jp.

PMID: 30389031
DOI: 10.1016/S2352-3026(18)30171-6

No abstract available

Publication types

Randomized Controlled Trial

MeSH terms

Area Under Curve
Busulfan / therapeutic use*
Cyclophosphamide / therapeutic use
Female
Graft Rejection / drug therapy*
Graft Rejection / mortality
Hematopoietic Stem Cell Transplantation*
Hepatic Veno-Occlusive Disease / drug therapy*
Humans
Male
Randomized Controlled Trials as Topic
Survival Analysis
Transplantation Conditioning
Vidarabine / analogs & derivatives
Vidarabine / therapeutic use
Young Adult

Substances

Cyclophosphamide
Vidarabine
Busulfan
fludarabine